BCG vaccine extensively used even in countries where efficacy against pulmonary tuberculosis is negligible. A number of possible reasons for the variable efficacy of BCG in different countries have been proposed. None have been proven, some have been disproved, and none can explain the lack of efficacy in both low-TB burden countries (US) and high-TB burden countries (India). The reasons for variable efficacy have been discussed at length in a WHO document on BCG. BCG has protective effects against some non-tuberculosis mycobacteria. BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with
Inoculation theory of tons in a single day. The Federal Trade Commission doesn't think that's significant." Hunt used this real-life message as an inoculation treatment in his research (Lessne and Didow, 1987). He used the corrective campaign by the FTC as the attack on the positive attitude toward Chevron. The results indicated that a supportive treatment offered less resistance than a refutational treatment. The other discovery was that when an inoculative treatment is received, but no attack is followed there is a drop in attitude. One of the major limitations in this study was that Hunt did not allow a time elapse